Veterinary Parasiticide Felpreva® (tigolaner / emodepside / praziquantel) Receives Positive Opinion From European Committee for Medicinal Products for Veterinary Use (CVMP)
13 September 2021 - 10:00AM
Business Wire
- On approval, Felpreva® will be licensed for treatment in
cats with, or at risk from, mixed ectoparasite infestations and
endoparasite infections, and will be exclusively indicated when
ectoparasites, cestodes and nematodes are targeted at the same
time.
Vetoquinol (Paris: VETO) today announced that the European
Medicines Agency’s Committee for Medicinal Products for Veterinary
Use (CVMP) has adopted a positive opinion recommending the granting
of a marketing authorization of Felpreva® spot-on solution
(tigolaner, emodepside, praziquantel). Felpreva® is proposed to
treat endoparasite infestations, as well as for treatment and
control of ectoparasites in cats.1
Felpreva® is a fixed combination product in the form of a
spot-on parasiticide solution for the treatment of cats when
ectoparasites, cestodes and nematodes are targeted at the same
time.1
“We are delighted to receive this positive opinion from the CVMP
for Felpreva® for the treatment and prevention of fleas, worms,
ticks and mites in cats. The parasiticide market is one of
Vetoquinol’s key strategic therapy areas and today’s milestone
marks Vetoquinol’s ongoing commitment to this essential category of
veterinary medicines,” said Matthieu Frenchin, CEO of
Vetoquinol.
Following an anticipated positive decision from the European
Medicines Agency on Vetoquinol’s application for marketing
authorization of Felpreva®, the veterinary medicinal product is
expected to be available to veterinarians across Europe in
2022.
For any specific enquiries about Felpreva®, please email:
juliana.carrer@vetoquinol.com
ENDS
References
1 EMA Summary of Positive Opinion – Felpreva. 2021. Available
from: https://www.ema.europa.eu/en/
medicines/veterinary/summaries-opinion/felpreva [Accessed 10
September 2021].
About Vetoquinol
Vetoquinol is a leading global animal health company committed
to delivering breakthrough therapies that improve the lives of
animals and support the diverse needs of veterinarians around the
world.
With a range of successful and trusted veterinary parasiticide
products, Vetoquinol has rapidly become an important player in the
global companion animal veterinary parasiticides market.
As an independent family-owned company, focussed on veterinary
medicines, Vetoquinol designs, develops and sells veterinary drugs
and non-medicinal products in Europe, the Americas and the Asia
Pacific region.
Since its foundation in 1933, Vetoquinol has been focussed on
creating strong mutually beneficial partnerships with veterinary
professionals, building a genuine relationship of trust with its
customers, in line with its mission to “achieve more together”.
Vetoquinol employed 2,525 people as of June 30th, 2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO).
For further information, go to: www.vetoquinol.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005267/en/
MIND+MATTER (Vetoquinol’s PR Partner agency) Luke Hopkins
Email: luke.hopkins@ashfieldhealth.com
VETOQUINOL International Range Manager – Companion Animal
Parasiticides Juliana Carrer Email: juliana.carrer@vetoquinol.com
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024